Loading...
Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient
CAR-T–cell therapy normally requires the patient’s own healthy T cells. An allogeneic CAR-T bridging therapy could rescue lymphopenic patients.
Na minha lista:
| Udgivet i: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6058233/ https://ncbi.nlm.nih.gov/pubmed/30026294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018017004 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|